TWI798173B - 神經活性類固醇，其組合物及用途 - Google Patents

神經活性類固醇，其組合物及用途 Download PDF

Info

Publication number
TWI798173B
TWI798173B TW106107640A TW106107640A TWI798173B TW I798173 B TWI798173 B TW I798173B TW 106107640 A TW106107640 A TW 106107640A TW 106107640 A TW106107640 A TW 106107640A TW I798173 B TWI798173 B TW I798173B
Authority
TW
Taiwan
Prior art keywords
hours
dose
days
compound
individual
Prior art date
Application number
TW106107640A
Other languages
English (en)
Chinese (zh)
Other versions
TW201733592A (zh
Inventor
史帝芬 傑 凱恩思
海倫 科昆皇
Original Assignee
美商賽吉醫療公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商賽吉醫療公司 filed Critical 美商賽吉醫療公司
Publication of TW201733592A publication Critical patent/TW201733592A/zh
Application granted granted Critical
Publication of TWI798173B publication Critical patent/TWI798173B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
TW106107640A 2016-03-08 2017-03-08 神經活性類固醇，其組合物及用途 TWI798173B (zh)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201662305279P 2016-03-08 2016-03-08
US62/305,279 2016-03-08
US201662355174P 2016-06-27 2016-06-27
US62/355,174 2016-06-27
US201662355669P 2016-06-28 2016-06-28
US62/355,669 2016-06-28
US201662360758P 2016-07-11 2016-07-11
US201662360762P 2016-07-11 2016-07-11
US62/360,762 2016-07-11
US62/360,758 2016-07-11

Publications (2)

Publication Number Publication Date
TW201733592A TW201733592A (zh) 2017-10-01
TWI798173B true TWI798173B (zh) 2023-04-11

Family

ID=59789807

Family Applications (2)

Application Number Title Priority Date Filing Date
TW106107640A TWI798173B (zh) 2016-03-08 2017-03-08 神經活性類固醇，其組合物及用途
TW112108775A TW202400182A (zh) 2016-03-08 2017-03-08 神經活性類固醇，其組合物及用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW112108775A TW202400182A (zh) 2016-03-08 2017-03-08 神經活性類固醇，其組合物及用途

Country Status (20)

Country Link
US (4) US20200306265A1 (cg-RX-API-DMAC7.html)
EP (1) EP3426257A4 (cg-RX-API-DMAC7.html)
JP (3) JP6838074B2 (cg-RX-API-DMAC7.html)
KR (3) KR102408399B1 (cg-RX-API-DMAC7.html)
CN (2) CN113616661A (cg-RX-API-DMAC7.html)
AU (2) AU2017229656B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018067998A2 (cg-RX-API-DMAC7.html)
CA (2) CA3017172C (cg-RX-API-DMAC7.html)
HK (1) HK1258616A1 (cg-RX-API-DMAC7.html)
IL (2) IL261658B2 (cg-RX-API-DMAC7.html)
JO (1) JOP20170059B1 (cg-RX-API-DMAC7.html)
MA (1) MA43815A (cg-RX-API-DMAC7.html)
MX (2) MX391122B (cg-RX-API-DMAC7.html)
NZ (1) NZ785712A (cg-RX-API-DMAC7.html)
PH (2) PH12022551313A1 (cg-RX-API-DMAC7.html)
RU (2) RU2022102537A (cg-RX-API-DMAC7.html)
SG (1) SG11201807785VA (cg-RX-API-DMAC7.html)
TW (2) TWI798173B (cg-RX-API-DMAC7.html)
WO (1) WO2017156103A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201805905B (cg-RX-API-DMAC7.html)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014528485A (ja) 2011-10-14 2014-10-27 セージ セラピューティクス， インコーポレイテッド ３，３−二置換１９−ノルプレグナン化合物およびその使用
BR112014018110B1 (pt) 2012-01-23 2022-06-07 Sage Therapeutics, Inc Composições farmacêutica aquosas formuladas para administração parenteral e uso de alopregnanolona e sulfobutiléter-b-ciclodextrina
IL294306B2 (en) 2012-08-21 2024-01-01 Sage Therapeutics Inc Methods of treating epilepsy or status epilepticus
US20150313915A1 (en) 2012-11-30 2015-11-05 The Regents Of The University Of California Anticonvulsant activity of steroids
WO2014169831A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof
RS58297B1 (sr) 2013-04-17 2019-03-29 Sage Therapeutics Inc 19-nor c3,3-disupstituisani c21-n-pirazolil steroidi i postupci za njihovu upotrebu
AU2014256228C1 (en) 2013-04-17 2017-09-14 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
WO2014169836A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
BR112016000975B1 (pt) 2013-07-19 2020-10-06 Sage Therapeutics, Inc. Compostos esteróides neuroativos e composições compreendendo os mesmos
RS61370B1 (sr) 2013-08-23 2021-02-26 Sage Therapeutics Inc Neuroaktivni steroidi, njihove kompozicije i upotreba
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
CN118344424A (zh) 2014-10-16 2024-07-16 萨奇治疗股份有限公司 靶向cns障碍的组合物和方法
DK3206493T3 (da) 2014-10-16 2020-08-10 Sage Therapeutics Inc Sammensætninger og fremgangsmåder til behandling af cns-forstyrrelser
SI3224269T1 (sl) 2014-11-27 2020-10-30 Sage Therapeutics, Inc. Sestavki in metode za zdravljenje CNS motenj
ES2857082T3 (es) 2015-01-26 2021-09-28 Sage Therapeutics Inc Composiciones y métodos para el tratamiento de trastornos del SNC
ES2935476T3 (es) 2015-02-20 2023-03-07 Sage Therapeutics Inc Esteroides neuroactivos, composiciones y usos de los mismos
US20200306265A1 (en) 2016-03-08 2020-10-01 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
WO2018013615A1 (en) 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C7, c12, and c16 substituted neuroactive steroids and their methods of use
AU2017297375B2 (en) 2016-07-11 2022-09-15 Sage Therapeutics, Inc. C17, C20, and C21 substituted neuroactive steroids and their methods of use
MA46042A (fr) 2016-08-23 2019-07-03 Sage Therapeutics Inc Stéroïde c21-n-pyrazolyle 3-disubstitué en 19-nor c3 cristallin
EP3579842A4 (en) 2017-02-10 2020-12-23 Asarina Pharma AB 3-BETA-HYDROXY-5-ALPHA-PRÉGNAN-20-ONE FOR USE IN THE TREATMENT OF ESSENTIAL TREMMENTS
AU2018327357B2 (en) * 2017-09-07 2024-08-22 Sage Therapeutics, Inc. Neuroactive steroids and their methods of use
WO2019075362A1 (en) * 2017-10-12 2019-04-18 Sage Therapeutics, Inc. METHOD OF TREATING CENTRAL NERVOUS SYSTEM DISORDERS WITH NEUROSTEROIDS AND GABAERGIC COMPOUNDS
KR20200085837A (ko) * 2017-11-10 2020-07-15 마리누스 파마슈티컬스 인코포레이티드 유전적 간질 질환 치료에 사용하기 위한 가낙솔론의 용도
EP4484440A3 (en) 2017-12-08 2025-03-26 Sage Therapeutics, Inc. Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders
MX2020008182A (es) * 2018-02-11 2020-09-22 Jiangsu Hansoh Pharmaceutical Group Co Ltd Reguladores de derivados esteroides, metodo para prepararlos y usos de los mismos.
JP2021527092A (ja) * 2018-06-12 2021-10-11 セージ セラピューティクス， インコーポレイテッド １９−ノルｃ３，３−二置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法
EP3860595A4 (en) * 2018-11-05 2021-11-10 Ovid Therapeutics Inc. USE OF GABOXADOL, GANAXOLONE, AND ALLOPREGNANOLONE TO TREAT MOTION DISORDERS
CN109503694A (zh) * 2018-11-21 2019-03-22 苏州闻天医药科技有限公司 一种新型gabaa受体调节剂及其用途
US11266662B2 (en) 2018-12-07 2022-03-08 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of postpartum depression
JP7340023B2 (ja) * 2019-01-14 2023-09-06 ベイジン シュエンイー ファーマサイエンシズ カンパニー， リミテッド テトラゾロン置換ステロイド及びその使用
US11497754B2 (en) 2019-02-05 2022-11-15 Washington University Neurosteroids and enantiomers thereof for the prevention and treatment of neurodegenerative conditions
MX2021010744A (es) * 2019-03-04 2022-01-18 Praxis Prec Medicines Inc Metodos para el tratamiento de la perimenopausia y la menopausia.
SG11202112111WA (en) 2019-05-10 2021-11-29 Brii Biosciences Inc Pharmaceutical composition containing brexanolone, ganaxolone, or zuranolone, and use thereof
BR112021024033A2 (pt) 2019-05-31 2022-02-08 Sage Therapeutics Inc Esteroides neuroativos e suas composições
MX2022001553A (es) 2019-08-05 2022-04-18 Marinus Pharmaceuticals Inc Ganaxolona para su uso en el tratamiento del estado epileptico.
US10857163B1 (en) 2019-09-30 2020-12-08 Athenen Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
IL293525A (en) * 2019-12-06 2022-08-01 Marinus Pharmaceuticals Inc Ganaxolone for use in the treatment of multiple sclerosis complex
AU2021206712A1 (en) * 2020-01-12 2022-07-28 Brii Biosciences, Inc. Neuroactive steroids and pharmaceutical composition containing the same
US20230414636A1 (en) 2020-03-25 2023-12-28 Sage Therapeutics, Inc. Use of gabaa modulators for treatment of respiratory conditions
WO2022125408A1 (en) * 2020-12-07 2022-06-16 Marinus Pharmaceuticals, Inc Use of ganaxolone in treating an epilepsy disorder
CN112516086B (zh) * 2020-12-08 2022-05-20 武汉久安药物研究院有限公司 注射用布瑞诺龙脂肪乳及其制备方法
KR20230136599A (ko) * 2021-01-28 2023-09-26 세이지 테라퓨틱스, 인크. 성 기능장애의 치료를 위한 신경활성 스테로이드의용도
JP2024513581A (ja) * 2021-04-12 2024-03-26 セージ セラピューティクス， インコーポレイテッド 本態性振戦の治療
US12208103B1 (en) 2021-05-07 2025-01-28 Lipocine Inc. Compositions and methods for treating CNS disorders
US11337987B1 (en) * 2021-05-07 2022-05-24 Lipocine Inc. Compositions and methods for treating central nervous system disorders
US11969434B1 (en) 2022-08-29 2024-04-30 Lipocine Inc. Oral allopregnanolone compositions and methods of use
BR112024001518A2 (pt) 2021-07-28 2024-04-30 Sage Therapeutics Inc Formas cristalinas de um esteroide neuroativo
JP2025504069A (ja) * 2022-01-27 2025-02-06 ベルナップ ファーマシューティカルズ， エルエルシー オキシトシンを使用した治療方法
WO2023164385A1 (en) * 2022-02-28 2023-08-31 Sage Therapeutics, Inc. Neuroactive steroids for treatment of gastrointestinal diseases or conditions
US20250345345A1 (en) * 2022-04-26 2025-11-13 Praxis Precision Medicines, Inc. Methods for the treatment of neurological disorders
US12186327B2 (en) 2022-08-29 2025-01-07 Lipocine Inc. Oral allopregnanolone compositions and methods of use
WO2024059608A1 (en) * 2022-09-15 2024-03-21 Sage Therapeutics, Inc. Deuterated neuroactive steroids
CN115957332B (zh) * 2022-11-01 2023-10-10 北京华睿鼎信科技有限公司 透明质酸酶稳定的布瑞诺龙纳米晶及其制备方法与应用
WO2024230797A1 (zh) * 2023-05-11 2024-11-14 上海枢境生物科技有限公司 甾体类化合物、制备方法及其用途

Family Cites Families (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3117142A (en) 1961-03-01 1964-01-07 Roussel Uclaf Novel preparation of estradiol and estrone
US3169134A (en) 1963-03-21 1965-02-09 Searle & Co 2, 3-oxygenated-17alpha-methyl-5alpha-androstan-17beta-ols
BE754111A (fr) 1969-07-29 1971-01-29 Upjohn Co Nouveaux 7alpha- et 7beta-methyl-3alpha,5alpha- cycloandrostanes et composes analogues 19-nor et leur procede de preparation
US3943124A (en) 1970-12-17 1976-03-09 Gordon Hanley Phillipps Chemical compounds
GB1430942A (en) 1972-05-05 1976-04-07 Glaxo Lab Ltd 21-substituted 3alpha-hydroxy pregnanes
US3983111A (en) 1972-05-05 1976-09-28 Glaxo Laboratories Limited Steroidal anaesthetics of the pregnane and 19-norpregnane series
US3865939A (en) 1973-02-23 1975-02-11 Procter & Gamble Edible oils having hypocholesterolemic properties
US4071625A (en) 1974-05-13 1978-01-31 Richardson-Merrell Inc. 19-Oxygenated-5α-androstanes for the enhancement of libido
US4192871A (en) 1976-01-06 1980-03-11 Glaxo Laboratories Limited Chemical compounds
GB1570394A (en) 1976-01-06 1980-07-02 Glaxo Lab Ltd 11-acyloxy-3-hydroxy steroids
GB1581234A (en) 1976-04-05 1980-12-10 Glaxo Operations Ltd 11a - amino - 3a - hydroxysteroids
SE8600632D0 (sv) 1986-02-13 1986-02-13 Kabivitrum Ab Novel pharmaceutical composition
US5120723A (en) * 1987-08-25 1992-06-09 University Of Southern California Method, compositions, and compounds for modulating brain excitability
US5319115A (en) 1987-08-25 1994-06-07 Cocensys Inc. Method for making 3α-hydroxy, 3β-substituted-pregnanes
US5232917A (en) 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5719197A (en) 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
EP0603312A4 (en) 1991-09-13 1995-06-07 Cocensys Inc NEW GABA A RECEPTOR WITH STEROID BINDING POINTS.
JP4008024B2 (ja) 1993-05-24 2007-11-14 パーデュー、ファーマ、リミテッド、パートナーシップ Ｇａｂａａレセプター複合体と相互作用させるための化合物
EP0656365B1 (en) 1993-12-02 1997-04-09 Akzo Nobel N.V. Substituted 2beta-morpholinoandrostane derivatives
DK1038880T3 (da) 1994-02-14 2008-03-03 Euro Celtique Sa Androstaner og pregnaner til allosterisk modulering af GABA-receptor
US5939545A (en) 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
BR9507200A (pt) 1994-03-25 1997-09-16 Isotechnika Inc Melhora da eficácia de drogas por deuteração
WO1996003421A1 (en) 1994-07-21 1996-02-08 Pharmacia & Upjohn Company Neurologically active aminosteroids
PT808325E (pt) 1994-11-23 2001-06-29 Cocensys Inc Series de androstanos e pregnanos para modulacao alosterica do receptor de gaba
US6780853B1 (en) 1995-06-06 2004-08-24 Euro-Celtique S.A. Neuroactive steroids of the androstane and pregnane series
KR19990022323A (ko) 1995-06-06 1999-03-25 씨. 랜 낸시 안드로스탄 및 프레그난 시리즈의 신경활성 스테로이드
JP4313435B2 (ja) 1995-07-24 2009-08-12 トラスティーズ オブ ボストン ユニバーシティー プレグネノロンサルフェート誘導体によるｎｍｄａレセプター活性の抑制
WO1998005337A1 (en) 1996-08-01 1998-02-12 Cocensys, Inc. Use of gaba and nmda receptor ligands for the treatment of migraine headache
US7630757B2 (en) 1997-01-06 2009-12-08 Flint Hills Scientific Llc System for the prediction, rapid detection, warning, prevention, or control of changes in activity states in the brain of a subject
US6245757B1 (en) 1997-10-03 2001-06-12 Research Corporation Technologies, Inc. Use of progestins to treat ischemic event
AU756001B2 (en) 1998-03-11 2003-01-02 Umecrine Mood Ab Epiallopregnanolone in the treatment of CNS disorders
US20020198174A1 (en) 2001-05-07 2002-12-26 Allergan Sales, Inc. Disinfecting and solubilizing steroid compositions
US6376531B1 (en) 1998-11-13 2002-04-23 Rupert Charles Bell Method of treatment using deuterium compounds
US20030236236A1 (en) 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
EP1104760B1 (en) 1999-12-03 2003-03-12 Pfizer Products Inc. Sulfamoylheteroaryl pyrazole compounds as anti-inflammatory/analgesic agents
US6613308B2 (en) 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US20020072509A1 (en) 2000-10-11 2002-06-13 Stein Donald Gerald Methods for the treatment of a traumatic central nervous system injury
GR1003861B (el) 2000-12-29 2002-04-11 Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa.
CA2443266A1 (en) 2001-02-13 2002-08-22 University Of Florida A bi-directional dual promoter complex with enhanced promoter activity for transgene expression in eukaryotes
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US20030032638A1 (en) 2001-05-24 2003-02-13 Kim John J. Delivery of benzodiazepines through an inhalation route
US7090830B2 (en) 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
CA2641760A1 (en) 2001-05-24 2002-11-28 Alexza Pharmaceuticals, Inc. Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route
JP2003063965A (ja) 2001-06-13 2003-03-05 Otsuka Pharmaceut Factory Inc 注射用シロスタゾール水性製剤
CA2496867A1 (en) 2002-08-28 2004-03-11 Hollis-Eden Pharmaceuticals, Inc. Therapeutic treatment methods
US9339508B2 (en) 2003-01-17 2016-05-17 Mapreg Use of 3-methoxy-pregnenolone for the preparation of a drug for treating a traumatic brain injury
EP1626980A4 (en) 2003-05-29 2007-07-04 Univ Washington NEUROACTIVE 13,24-CYCLO-18,21-DINORCHOLANES AND STRUCTURELY RELATED PENTACYCLIC STEROIDS
US7816074B2 (en) 2003-07-31 2010-10-19 The Research Foundation Of State University Of New York α4 β2 δGABA-A receptors as a strategy for PMS and alcoholism
GB0321607D0 (en) 2003-09-15 2003-10-15 Vectura Ltd Manufacture of pharmaceutical compositions
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US7892483B2 (en) 2004-03-12 2011-02-22 Cipla Limited Sterilization process
WO2005105822A2 (en) 2004-04-23 2005-11-10 Euro-Celtique S.A. 3-alpha-hydroxy 21-n- heteroaryl-pregnane derivatives for modulation of brain excitability and a process for the production thereof
US20060063707A1 (en) 2004-09-17 2006-03-23 Lifelike Biomatic, Inc. Compositions for enhancing memory and methods therefor
US8604011B2 (en) 2004-09-27 2013-12-10 The Regents Of The University Of California Therapy for treatment of chronic degenerative brain diseases and nervous system injury
AU2005330504B2 (en) 2004-09-29 2010-10-28 Harbor Biosciences, Inc. Steroid analogs and characterization and treatment methods
BRPI0608087A2 (pt) 2005-02-15 2009-11-10 Elan Pharma Int Ltd formulações injetáveis e em aerossol de benzodiazepina em nanopartìculas
RS52471B (sr) 2005-03-24 2013-02-28 Emory University Režimi doziranja za lečenje traumatske povrede mozga progesteronom
EP1868593A2 (en) 2005-04-07 2007-12-26 Hythiam, Inc. Improved methods of and compositions for the prevention of anxiety, substance abuse, and dependence
US20110319386A1 (en) 2005-08-26 2011-12-29 Braincells Inc. Neurogenesis by muscarinic receptor modulation
EA017290B1 (ru) 2005-11-28 2012-11-30 Домейн Раша Инвестментс Лимитед Композиции на основе ганаксолона
US20070287931A1 (en) 2006-02-14 2007-12-13 Dilorenzo Daniel J Methods and systems for administering an appropriate pharmacological treatment to a patient for managing epilepsy and other neurological disorders
EP2029564A4 (en) * 2006-05-22 2010-01-13 Vanda Pharmaceuticals Inc TREATMENT OF DEPRESSIVE DISORDERS
BRPI0716604A2 (pt) 2006-09-08 2013-04-09 Braincells Inc combinaÇÕes contendo um derivado de 4-acilaminopiridina
US20090239942A1 (en) 2006-09-15 2009-09-24 Cloyd James C Topiramate Compositions and Methods of Making and Using the Same
US20090203658A1 (en) 2007-01-08 2009-08-13 Duke University Neuroactive steroid compositions and methods of use therefor
US20090074677A1 (en) * 2007-01-08 2009-03-19 Duke University Neuroactive steroid compositions and methods of use therefor
US7813811B2 (en) 2007-02-08 2010-10-12 Neuropace, Inc. Refillable reservoir lead systems
LT2545939T (lt) 2007-04-11 2021-03-10 Biomarin Pharmaceutical Inc. Tetrahidrobiopterinas, skirtas gydyti ligas, susijusias supadidėjusiu fenilalanino kiekiu
US8530463B2 (en) 2007-05-07 2013-09-10 Hale Biopharma Ventures Llc Multimodal particulate formulations
WO2008154579A1 (en) 2007-06-11 2008-12-18 University Of Southern California Allopregnanolone in a method for enhancing neurological function (alzheimer disease)
AU2008265898B2 (en) 2007-06-15 2013-11-28 Research Triangle Institute Androstane and pregnane steroids with potent allosteric GABA receptor chloride ionophore modulating properties
GB0711948D0 (en) 2007-06-20 2007-08-01 Bionature E A Ltd Neurosteriod compounds
WO2009000038A1 (en) 2007-06-28 2008-12-31 Cnsbio Pty Ltd Combination methods and compositions for treatment of neuropathic pain
US20100297181A1 (en) 2007-12-26 2010-11-25 Eisai R&D Management Co., Ltd. AMPA Receptor Antagonists for Epilepsy, Mental Disorders or Deficits in Sensory Organ
JP2011508775A (ja) 2008-01-03 2011-03-17 ビオマリン プハルマセウトイカル インコーポレイテッド Ｂｈ４応答性状態を治療するためのプテリン類似体
US20090198145A1 (en) 2008-02-06 2009-08-06 Chow Harrison Compositions, methods, and systems for rapid induction and maintenance of continuous rem sleep
US8729070B2 (en) 2008-02-20 2014-05-20 Targia Pharmaceuticals CNS pharmaceutical compositions and methods of use
WO2010063030A2 (en) 2008-11-30 2010-06-03 Feigelson, Daniel Dermal application of vasoconstrictors
CZ2008434A3 (cs) 2008-07-10 2009-12-09 Ústav organické chemie a biochemie Akademie ved CR, v. v. i. Pregnanové anionické slouceniny, zpusob jejich výroby a jejich použití
SMT202000257T1 (it) 2008-10-10 2020-07-08 Vm Discovery Inc Composizioni e metodi per il trattamento dei disturbi da uso di alcol, dolore e altre malattie
US20110318271A1 (en) * 2008-12-29 2011-12-29 University Of Tartu Arginase Inhibitors for the Treatment of Depression
WO2010088409A2 (en) 2009-01-30 2010-08-05 Emory University Methods of neuroprotection using neuroprotective steroids and a vitamin d
WO2010107922A1 (en) 2009-03-17 2010-09-23 Duke University Neuroactive steroid compositions and methods of use for lowering cholesterol
CZ303037B6 (cs) * 2009-05-28 2012-03-07 Ústav organické chemie a biochemie, Akademie ved CR, v. v. i. Deriváty pregnanolonu substituované v poloze 3alfa, zpusob jejich výroby a jejich použití
WO2011079047A1 (en) * 2009-12-23 2011-06-30 Drugtech Corporation Methods for reducing the occurrence of preterm delivery and other pregnancy-related conditions
KR101747476B1 (ko) 2010-01-21 2017-06-14 드로브리지 파마슈티컬스 피티와이 엘티디 마취 제제
US8747365B2 (en) 2010-11-03 2014-06-10 Sanofi-Aventis Deutschland Gmbh Needle cannula containing medicament
WO2012075286A2 (en) 2010-12-01 2012-06-07 The Regents Of The University Of California Intrapulmonary benzodiazepine for the treatment and prevention of seizures
CZ303443B6 (cs) 2011-02-15 2012-09-12 Ústav organické chemie a biochemie Akademie ved CR, v.v.i. Deriváty pregnanolonu substituované v poloze 3alfa kationickou skupinou, zpusob jejich výroby, jejich použití a prostredek je obsahující
WO2012116290A2 (en) 2011-02-25 2012-08-30 Washington University Neuroactive 17(20)-z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same
FR2973031B1 (fr) 2011-03-23 2013-11-29 Univ Strasbourg Derives de l'allopregnanolone et de l'epiallopregnanolone et leurs utilisations pour traiter un etat neuropathologique
US9084797B2 (en) 2011-05-23 2015-07-21 Besins Healthcare Luxembourg Sarl Progesterone treatment for improving sleep quality
EP2727473A4 (en) 2011-06-28 2015-05-06 Vivozon Inc COMBINATION OF EFFICIENT SUBSTANCES WITH SYNERGISTIC EFFECTS OF MULTIPLE TARGETING AND USE THEREOF
JP2014521662A (ja) * 2011-07-29 2014-08-28 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ＧＡＢＡＡ受容体のモジュレーターとしての新規な１７β−ヘテロアリール置換ステロイド
SMT202300232T1 (it) * 2011-09-08 2023-09-06 Sage Therapeutics Inc Steroidi neuroattivi, composizioni e relativi usi
US10478505B2 (en) 2011-09-23 2019-11-19 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
JP2014528485A (ja) 2011-10-14 2014-10-27 セージ セラピューティクス， インコーポレイテッド ３，３−二置換１９−ノルプレグナン化合物およびその使用
WO2013079624A1 (en) 2011-11-29 2013-06-06 Amino Up Chemical Co., Ltd. Composition comprising vicenin-2 having a beneficial effect on neurological and/or cognitive function
BR112014018110B1 (pt) 2012-01-23 2022-06-07 Sage Therapeutics, Inc Composições farmacêutica aquosas formuladas para administração parenteral e uso de alopregnanolona e sulfobutiléter-b-ciclodextrina
US20150175651A1 (en) 2012-06-15 2015-06-25 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US20140050789A1 (en) 2012-08-13 2014-02-20 The Regents Of The University Of California Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids
IL294306B2 (en) 2012-08-21 2024-01-01 Sage Therapeutics Inc Methods of treating epilepsy or status epilepticus
WO2014058736A1 (en) 2012-10-08 2014-04-17 Washington University Neuroactive 19-alkoxy-17(20)-z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same
US9757391B2 (en) 2012-11-09 2017-09-12 Goodchild Investments Pty Ltd Neuroactive steroids and their use to facilitate neuroprotection
US20150313915A1 (en) 2012-11-30 2015-11-05 The Regents Of The University Of California Anticonvulsant activity of steroids
JP6542127B2 (ja) 2012-12-18 2019-07-10 ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ 向神経活性１９−アルコキシ−１７−置換ステロイド、そのプロドラッグおよびそれを使用する処置方法
WO2014108808A2 (en) 2013-01-09 2014-07-17 Henry James Lorne Pharmaceutical formulations for the treatment and prevention of trauma-induced neuropathology and neurodegeneration
WO2014169831A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof
AU2014256228C1 (en) 2013-04-17 2017-09-14 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
RS58297B1 (sr) 2013-04-17 2019-03-29 Sage Therapeutics Inc 19-nor c3,3-disupstituisani c21-n-pirazolil steroidi i postupci za njihovu upotrebu
WO2014169836A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
BR112016000975B1 (pt) 2013-07-19 2020-10-06 Sage Therapeutics, Inc. Compostos esteróides neuroativos e composições compreendendo os mesmos
RS61370B1 (sr) 2013-08-23 2021-02-26 Sage Therapeutics Inc Neuroaktivni steroidi, njihove kompozicije i upotreba
TW201625661A (zh) * 2014-05-29 2016-07-16 賽吉醫療公司 神經活性類固醇，其組合物及其用途
US10246482B2 (en) * 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) * 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
EP4059522A1 (en) 2015-02-06 2022-09-21 Marinus Pharmaceuticals, Inc. Intravenous ganaxolone formulations and their use in treating status epilepticus and other seizure disorders
GB2541015A (en) 2015-08-06 2017-02-08 Ge Oil & Gas Uk Ltd Subsea flying lead
AU2016338916B2 (en) 2015-10-14 2021-12-23 The Regents Of The University Of California Enhancing beta cell replication and/or survival
US20200306265A1 (en) 2016-03-08 2020-10-01 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
KR20230050474A (ko) 2016-08-11 2023-04-14 오비드 테라퓨틱스 인크. 간질 장애의 치료를 위한 방법 및 조성물
US20180050107A1 (en) 2016-08-16 2018-02-22 Janssen Pharmaceutica Nv Neurosteroid compositions and methods of use thereof
US20180050005A1 (en) 2016-08-16 2018-02-22 Janssen Pharmaceutica Nv Concentrated Solution of 17-Hydroxydocosahexaenoic Acid
KR102630701B1 (ko) 2016-09-07 2024-01-29 글리아, 엘엘씨 두개 신경의 약리학적 피부 활성화에 의한 신경변성 질환과 관련된 증상의 치료
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
WO2018169798A1 (en) 2017-03-11 2018-09-20 The Regents Of The University Of California Mitigation of cns disorders by combination therapy using neurosteroids, and ampa blockers
CN110520131A (zh) 2017-04-18 2019-11-29 马瑞纳斯制药公司 缓释可注射的神经类固醇制剂
US20180338959A1 (en) 2017-05-24 2018-11-29 Ovid Therapeutics Inc. Treatment of depressive disorders
US11752115B2 (en) 2017-06-21 2023-09-12 The Board Of Trustees Of The University Of Illinois PPAR-alpha agonist treatment of neuropsychiatric disorders
WO2018237282A1 (en) 2017-06-23 2018-12-27 The Board Of Trustees Of The University Of Illinois Treatment of neuropsychiatric disorders with neurosteroids and analogues thereof
EP3642206A4 (en) 2017-06-23 2021-04-07 The Regents of The University of California INCREASED GABA ABILITY TO MODULATE IMMUNE REACTIONS
KR20200085837A (ko) 2017-11-10 2020-07-15 마리누스 파마슈티컬스 인코포레이티드 유전적 간질 질환 치료에 사용하기 위한 가낙솔론의 용도
CA3099089A1 (en) 2018-05-04 2019-11-07 Acerus Pharmaceuticals Corporation Neurosteroid derivatives and uses thereof
EP3876935A4 (en) 2018-11-08 2022-08-17 Varsona Therapeutics, Inc. TOPICAL FORMULATIONS OF 5-A REDUCTASE INHIBITORS AND THEIR USES
AU2019384157A1 (en) 2018-11-21 2021-06-17 Certego Therapeutics Inc. Gaboxadol for reducing risk of suicide and rapid relief of depression
US11266662B2 (en) 2018-12-07 2022-03-08 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of postpartum depression
PH12021551396A1 (en) 2018-12-14 2022-05-11 Acerus Biopharma Inc Active ester derivatives of testosterone, compositions and uses thereof

Also Published As

Publication number Publication date
US20230355639A1 (en) 2023-11-09
PH12018501923A1 (en) 2019-07-01
WO2017156103A1 (en) 2017-09-14
US20220023313A1 (en) 2022-01-27
IL261658B1 (en) 2023-03-01
NZ745870A (en) 2025-03-28
PH12018501923B1 (en) 2024-06-28
JP2021073309A (ja) 2021-05-13
CN109414444A (zh) 2019-03-01
JOP20170059B1 (ar) 2021-08-17
CN113616661A (zh) 2021-11-09
IL261658A (en) 2018-10-31
BR112018067998A2 (pt) 2019-04-16
IL300422A (en) 2023-04-01
KR20240157128A (ko) 2024-10-31
SG11201807785VA (en) 2018-10-30
NZ785712A (en) 2025-03-28
RU2766155C2 (ru) 2022-02-08
PH12022551313A1 (en) 2024-06-24
TW201733592A (zh) 2017-10-01
US20200171049A1 (en) 2020-06-04
US10940156B2 (en) 2021-03-09
AU2022283769A1 (en) 2023-02-02
KR102408399B1 (ko) 2022-06-13
EP3426257A1 (en) 2019-01-16
RU2018135079A3 (cg-RX-API-DMAC7.html) 2020-04-16
ZA201805905B (en) 2019-07-31
TW202400182A (zh) 2024-01-01
HK1258616A1 (zh) 2019-11-15
CA3017172A1 (en) 2017-09-14
IL300422B1 (en) 2025-11-01
AU2017229656A1 (en) 2018-10-11
MX391122B (es) 2025-03-19
JP2019511488A (ja) 2019-04-25
MX2022003896A (es) 2022-04-19
MA43815A (fr) 2021-04-07
RU2022102537A (ru) 2022-03-30
EP3426257A4 (en) 2019-11-13
JP6838074B2 (ja) 2021-03-03
AU2022283769B2 (en) 2025-03-06
IL261658B2 (en) 2023-07-01
CA3158448A1 (en) 2017-09-14
US20200306265A1 (en) 2020-10-01
AU2017229656B2 (en) 2022-09-29
RU2018135079A (ru) 2020-04-08
MX2018010902A (es) 2019-03-06
KR20180115797A (ko) 2018-10-23
KR20220084418A (ko) 2022-06-21
JP2023093723A (ja) 2023-07-04
CA3017172C (en) 2023-03-14
US11554125B2 (en) 2023-01-17

Similar Documents

Publication Publication Date Title
TWI798173B (zh) 神經活性類固醇，其組合物及用途
KR102491549B1 (ko) 신경활성 스테로이드, 그의 조성물, 및 용도